Understanding how breast cancer patients use risk information from genomic tests by DeFrank, Jessica T. et al.
Understanding how breast cancer patients use risk information
from genomic tests
Jessica T DeFrank1, Lisa A Carey2, and Noel T Brewer1,3
1Gillings School of Global Public Health, University of North Carolina, Chapel Hill
2School of Medicine, University of North Carolina, Chapel Hill
3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Abstract
Background—We sought to examine how patients’ treatment decisions incorporate potentially
conflicting information from standard clinical indicators (e.g., tumor size) and genomic tests for
breast cancer recurrence risk.
Methods—Participants were 77 early stage breast cancer survivors who previously received
genomic testing. They read six hypothetical vignettes that varied recurrence risk indicated by
standard tests (low or high risk) coupled with the genomic test (low, intermediate or high risk).
For each vignette, women reported their perceived recurrence risk and treatment preferences.
Results—Test results indicating high recurrence risk increased perception of risk and preference
for chemotherapy (p<.001 for all). Perceived risk explained (i.e., mediated) the effect of test
results on chemotherapy preferences. When test results conflicted, women gave more weight to
genomic over standard test results.
Discussion—Hypothetical genomic test results had the intended effect of influencing women’s
perceptions of recurrence risk and interest in chemotherapy.
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As genomic testing becomes more common in clinical care for cancer (Morris & Carey,
2007), understanding how patients use information from these tests has increased in
importance. One such genomic test, Oncotype DX, predicts 10 year risk of distant
recurrence among early stage breast cancer patients (estrogen-receptor positive). The test
examines the activity of 21 genes in breast tumors (Paik et al., 2004; Sparano et al., 2008)
and offers a more precise risk estimate than from standard methods for assessing recurrence
risk (such as tumor size and grade)(Albain et al., 2010; Albain et al., 2010; Dowsett et al.,
2010; Habel et al., 2006; Paik et al., 2006). Test results can help women and their doctors
make decisions about whether to include chemotherapy in their treatment plans (Gianni et
al., 2005). Women with high recurrence risk may opt for more aggressive treatment (i.e.,
adjuvant chemotherapy), whereas those with low recurrence risk may forgo such treatment
and its potential side effects. The American Society of Clinical Oncology recently endorsed
Oncotype DX as part of their clinical guidelines (Harris et al., 2007).
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While genomic tests provide potentially useful information for guiding treatment decisions
(Lo et al., 2010; Oratz et al., 2007; Oratz et al., 2011; Tzeng et al., 2010), their results can
conflict with information from standard clinical indicators of recurrence risk (which we will
call “standard tests”, for the sake of simplicity). Oncotype DX reports a low risk result for
between 33% and 50% of women with early stage breast cancer whose standard test results
suggest are at high risk for recurrence (Paik, 2007; Van De Vijver et al., 2002).
Recategorizing from high to low risk is likely more common in the US where different
clinical criteria are used to determine risk compared to the St. Gallen approach commonly
used in Europe (Van De Vijver et al., 2002).
Our previous research, which used hypothetical recurrence risk information to understand
how breast cancer patients incorporate potentially conflicting test results, suggested that
some would be reluctant to forgo chemotherapy if genomic tests indicated low risk and
standard tests indicated high risk(Brewer et al., 2009). This finding suggested that one of the
main promises of genomic testing, allowing many women to safely forgo unnecessary
treatment, would not be fulfilled. However, previous research predated common clinical use,
and patient familiarity with genomics and these assays’ findings could differ today (O’Neill
et al., 2007). Furthermore, the previous study did not assess the role of perceived risk in
these treatment decisions. Presumably, high recurrence risk test results influence patients’
beliefs about recurrence, which then alter treatment choices (Brewer et al., 2007), but this
hypothesis has never been tested.
The present study extends our previous work by examining effects of hypothetical genomic
and standard test results among a sample of patients who received the Oncotype DX test as
part of clinical care for early-stage breast cancer. We hypothesized that results indicating
higher risk of recurrence would increase women’s interest in chemotherapy. Furthermore,
we hypothesized that this association would be due to increases in women’s estimates of
their chances of having breast cancer return (i.e., mediation). Given that genomic testing is
performed in hormone receptor-positive breast cancer, and the results assume receipt of
adjuvant antiestrogen therapy, testing cannot meaningfully inform hormone therapy
decisions. Thus, we hypothesized that standard, but not genomic tests, indicating higher risk
would increase interest in hormone therapy. Finally, we hypothesized that information from
genomic tests would have a stronger impact on women’s treatment preferences when results
conflicted with the standard tests, because of a growing emphasis on genomic medicine in
clinical practice and the media (Guttmacher et al., 2002) and patients’ strong interest in
testing (O’Neill et al., 2007).
METHODS
Participants and Procedure
Eligible participants were women previously treated for early-stage breast cancer at the
University of North Carolina Breast Center (Chapel Hill, NC), whose medical records
indicated they received the Oncotype DX test between when it first became available in June
2004 through October 2008. Women eligible for Oncotype DX had stage I or II, node-
negative, hormone-receptor positive breast cancer; we also included one woman with node-
positive breast cancer, because the test validation includes some women with node-positive
breast cancers. Exclusion criteria were not being English-speaking or under age 18.
Researchers mailed study questionnaires between December 2008 and February 2009.
Women could complete a HIPAA authorization form to allow a review of their medical
records of cancer diagnosis and treatment. Women received a $15 incentive and up to two
follow-up letters to maximize response rates. The institutional review board of the
University of North Carolina approved the study protocol and materials.
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We used hypothetical vignettes to assess potential responses to genomic and standard testing
for breast cancer recurrence risk. Use of hypothetical vignettes is a well-accepted
methodology for understanding response to new cancer testing when information on actual
behavior is not available (Brewer et al., 2009; Lerman et al., 2000) or not easily recalled.
Standard and genomic test results—The study used a 2 × 3 within-subjects design
that varied hypothetical breast cancer recurrence risk from standard tests (low or high risk)
combined with those from genomic tests (low, intermediate, or high risk). Thus, all
participants received six vignettes: (1) standard and genomic tests both showed low
recurrence risk, (2) both tests showed high risk, (3) standard showed high risk and genomic
showed intermediate risk, (4) standard showed high risk and genomic showed low risk, (5)
standard showed low risk and genomic showed intermediate risk, and (6) standard showed
low risk and genomic showed high risk. We presented these six vignettes as a grid where the
first column presented the standard test result and the second column presented the
corresponding genomic test result. Researchers randomly assigned participants to receive the
vignettes in one of four counterbalanced orders. One order started with the vignette that had
low genomic and low standard recurrence risk results (low-low), followed by low-
intermediate, low-high, high-low, high-intermediate, and high-high. A second order started
with the vignette that had low genomic and high standard recurrence risk results (low-high),
followed by low-intermediate, low-low, high-high, high-intermediate, and high-low. The
third and fourth orders were the reverse of the first and second orders, respectively
Perceived risk and treatment—For each of the six vignettes respondents estimated their
hypothetical risk of breast cancer recurrence (which we refer to as “perceived risk”) from 0
to 100% and indicated their hypothetical treatment preference (chemotherapy, hormone
therapy, both or neither). We created two treatment preference variables to reflect whether
participants preferred chemotherapy treatment (yes or no) and preferred hormone treatment
(yes or no).
Attitudes toward tests—Two items assessed whether women felt their actual standard
and genomic test results could be trusted and were accurate. The 5-point response scale
ranged from “strongly disagree” to “strongly agree”, with higher scores reflecting higher
trust.
Participant demographic and medical characteristics—The survey assessed
demographic characteristics including age, race, income, time since cancer diagnosis, and
treatments received. One item assessed whether patients’ recalled that their actual standard
and genomic tests produced similar results (“yes”, “no” or “don’t know”). An item assessed
how often respondents needed help with written health-related materials; we refer to this as
literacy though we acknowledge that this single item measure may also tap other constructs.
Response options ranged from “never” to “always.” We assessed numeracy with a 3-item
scale (range 0–3 correct answers)(Schwartz et al., 1997).
We reviewed medical records of participants who signed HIPAA authorization forms (87%)
to confirm information on cancer treatments and to document actual recurrence risk using
two methods. The first method used women’s actual Oncotype DX scores that yielded a
recurrence score corresponding to a 10-year distant recurrence risk estimate (0–100%).
Recurrence risks were “low” if estimates were about 11% or less, “intermediate” for
estimates between 12% and 21%, and “high” for estimates greater than 21% as they appear
in Oncotype DX reports. We also calculated women’s 10-year risk for breast cancer
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recurrence using Adjuvant! Online using standard clinical information (e.g., grade, tumor
size) only.
Data analyses
The main outcome measures were perceived risk and treatment preferences. We used
generalized estimating equations, which accounted for repeated measurements, to examine
whether hypothetical standard test results, genomic test results and their interaction
predicted these two outcomes. We also examined whether perceived risk mediated the
association of hypothetical test results to chemotherapy treatment preferences (Baron et al.,
1986). GEE analyses yielded test statistics that follow a Z distribution. The Z statistic can be
interpreted as the chance difference in standard error units between the observed effect
parameter and the hypothesized null value if the null were true (Stokes et al., 2000); Z
statistics smaller than −1.96 and larger than 1.96 are considered statistically significant in
our study. As preliminary analyses showed that the order in which patients received
hypothetical genomic test results (e.g., whether high risk results came first) influenced
perceived risk of recurrence (p=.003), analyses controlled for vignette order. We used post-
hoc, paired t-tests and McNemar’s test to compare responses when hypothetical standard
and genomic test results were discordant. We conducted analyses in SAS v 9.2 (SAS
Institute Inc., Cary, NC, USA) using two-tailed tests and a critical alpha of .05.
RESULTS
Of 104 women we invited to participate, 78 completed surveys (response rate = 75%). We
excluded data from one participant who had incomplete survey data on treatment
preferences, resulting in a final sample of 77. Women’s mean age was 58 years (range 38–
83) (Table 1). Most were White (81%) and had health insurance (95%). Most women had
high literacy (81%), but fewer (31%) answered all numeracy items correctly. The average
time since cancer diagnosis was 17 months (range 4–54) with the majority of women (78%)
having been diagnosed within two years of the study. Most women had received hormone
therapy treatment (92%), and one-third (33%) had received chemotherapy.
Actual Test Results
During previous clinical care, women received Oncotype DX test results that indicated a
mean recurrence risk of 12% (range 4% to 32%). Mean risk estimates based on standard
clinical parameters that we integrated using Adjuvant! Online were 24% (range 15% to
54%). This difference was statistically significant (p=<.001). About 82% (55/67) of genomic
test results were lower by at least 5 percentage points than estimates based on standard test
results. About 17% of women recalled that their standard and genomic tests yielded different
recurrence risk estimates; 29% recalled that their test results produced similar results; while
54% of women were unsure or could not recall if their results were discordant.
Women trusted their genomic test results more than standard test results (mean scores 3.96,
SD=.70 and 3.71, SD=.81 respectively, p=.03). Women also thought genomic test results
were more accurate than standard test results (mean scores 3.89, SD=.73 and 3.70, SD=.83
respectively, p=.04). Trust and accuracy were highly correlated for both genomic (r=.86, p<.
001) and standard tests (r=.74, p<.001).
Hypothetical Test Results
Hypothetical standard and genomic tests that reported results with higher risk magnitudes
led women to state higher perceived risks of cancer recurrence (Figure 1) (z = 11.58 and
14.71 respectively, both p <.001). However, the association of genomic test results with
perceived risk did not vary by standard test results (p =.11 for interaction)
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Hypothetical standard and genomic test results indicating higher risk increased preference
for chemotherapy treatment (z = 6.10 and 6.65 respectively, both p <.001) (Figure 2a). The
effect of genomic test results on chemotherapy preferences varied by standard test results (p
<.001 for interaction). Post-hoc tests revealed that, when standard test results indicated low
risk, results of genomic tests had a strong effect on chemotherapy preferences (z = 8.00, p <.
001) (represented by the slope of bars 1–3, Figure 2a). When standard test results indicated
high risk, interest in chemotherapy was generally high, and genomic test results had a
smaller effect on chemotherapy preferences (z = 4.42, p <.001) (represented by the slope of
bars 4–6, Figure 2a).
Hypothetical standard test results reflecting higher risk increased preference for hormone
therapy treatment (z = 2.33, p =.02) (Figure 2b). However, genomic test results did not
affect preference for hormone therapy (z = 1.11, p =.27) nor was the interaction between
standard and genomic test results statistically significant (p=.64).
Mediation—We conducted mediation analyses to assess whether perceived risk was the
mechanism through which hypothetical test results influenced hypothetical preferences for
chemotherapy treatment. As previously reported, standard and genomic test results
indicating higher recurrence risk increased perceived risk of recurrence and preference for
chemotherapy. Higher perceived risk was associated with a higher likelihood of opting for
chemotherapy treatment, controlling for test results (p<.001). Effects of standard and
genomic test results on chemotherapy preferences were attenuated when controlling for
perceived risk (z values dropped from 6.10 to 3.53 and 6.65 to 4.00 respectively), suggesting
partial mediation (Figure 3). Thus, genomic and standard test results indicating higher
recurrence risk lead to greater perceived risk, which in turn, lead to an increased likelihood
of opting for chemotherapy treatment. We did not conduct mediation analyses for interest in
hormone treatment due to lack of association with genomic test results.
Moderation—Effects of hypothetical standard and genomic test results on hypothetical
treatment preferences were not modified by literacy, numeracy, trust, perceived accuracy,
whether patients received actual chemotherapy treatment, or patients’ actual recurrence risk
based on Oncotype DX and Adjuvant! Online scores (all p>.05). As half (54%) of patients
could not recall whether their actual results were similar or discordant, we did not examine
this variable as a potential moderator.
Discordant Test Results—A critical question concerned whether women gave more
weight to standard or genomic tests when hypothetical results were discordant. To address
this question, we compared risk perceptions and chemotherapy preferences in the two
“mismatched” results conditions (i.e., a low risk result from the standard test coupled with a
high risk result from the genomic test and vice versa). Mean perceived recurrence risk was
45% when standard test results were low but genomic test results were high, higher than the
mean of 30% when standard tests were high but genomic tests were low (p <.001,
represented by bars 3 and 4 respectively, Figure 1). Interest in chemotherapy also differed
when discordant genomic rather than standard tests showed high risk (84% vs. 65%, p <.
001; bars 3 and 4 of Figure 2a).
DISCUSSION
Genomic testing for breast cancer recurrence risk is becoming an increasingly important
component of cancer care in the age of personalized medicine. Test results can inform
women and their doctors of the likelihood of cancer recurrence, information that they can
use to make decisions about inclusion of chemotherapy treatment in addition to hormone
therapy. As we predicted, hypothetical genomic tests had the intended effect of influencing
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women’s perceptions of recurrence risk, which in turn, informed hypothetical decisions to
undergo or forgo chemotherapy treatment. These findings corroborate our previous finding
that most women understand that genomic test results provide information about the
potential for recurrence and that results can help inform treatment decisions (Brewer et al.,
2009; Richman et al., 2011).
Women’s receptivity to this risk information replicates our previous work showing that early
stage breast cancer patients’ recurrence risk beliefs corresponded closely to their actual
Oncotype DX results (Tzeng et al., 2010). These findings differ markedly from previous
work on communicating with women about BRCA 1/2 mutations that found that women
resisted information on breast cancer risk (Gurmankin et al., 2005). It may be that women
think differently about information relevant to treatment decisions (e.g., Oncotype DX) than
they do about risk for future disease (e.g., BRCA 1/2), a topic that merits additional
exploration in the same study.
As expected, hypothetical genomic test results had no influence on preference for hormone
therapy. The purpose of genomic tests is to inform decisions as they relate to chemotherapy
treatment, and thus results should not influence decisions to take hormone therapy.
However, differences in standard test results did inform preferences for hormone therapy.
While this pattern of findings suggests that women understand the specificity of meaning of
high genomic recurrence risk for treatment, the uniformly high interest in hormone therapy
may have obscured any differences.
About half of women in our study could not recall or were unsure whether their actual
standard and genomic test results received during clinical care were discordant. Women’s
limited ability to recall discordance of test results could be due to time since cancer
diagnosis which was 17 months on average, making details regarding similarity between
standard and genomic test results less salient. Low recall of whether actual results were
discordant might also indicate that some women did not understand what they were told
about their recurrence risk based on either test. Our previous research showed that although
many early stage breast cancer patients said they understood discussions about their
genomic test results, a third reported not fully understanding these discussions (Tzeng et al.,
2010). Furthermore, while recalled recurrence risk was highly concordant with the results
from Oncotype DX, a third could not recall their recurrence risk result (Tzeng et al., 2010).
Women in our study placed more weight on hypothetical genomic over standard test results
when the results conflicted. Women also perceived genomic tests as more accurate and
trustworthy compared to standard tests. These findings imply that one of the main promises
of genomic testing for patient decisions–helping some women to choose to forgo
chemotherapy and its potential side effects–is being realized and that women place high trust
in their test results. Women in our study were more willing to incorporate information from
genomic tests when standard test results indicate low rather than high recurrence risk.
Women still placed emphasis on standard clinic markers for recurrence (i.e., tumor size etc.)
and were less willing to forgo chemotherapy when these test results suggest that they are at a
higher risk of recurrence.
Strengths of the study are the inclusion of patients who received the Oncotype DX test–the
population for whom the findings are clinically relevant–and a high response rate. A
limitation is that participants were mostly Caucasian, well-educated and insured women who
received medical care from the same institution. The generalizability of our findings to more
diverse populations remains to be established. Future research on women’s reactions to
genomic testing should include socio-economically diverse samples from multiple clinics.
Our findings did not vary by factors such as demographic characteristics and numeracy.
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However, given our modest sample size, we view these moderation analyses as exploratory.
We also acknowledge that results from our hypothetical information may differ from real
life treatment decisions that happen with support and advice from a clinical care team. As
growing numbers of women undergo genomic testing, it will be important to replicate
findings from our survey with real treatment decisions.
Nonetheless, these findings suggest that many women understand the benefit of genomic
testing and properly use their results to inform treatment decisions. While many women will
be reluctant to forgo chemotherapy when standard test results indicate they are at risk of
recurrence, a sizable proportion reported they would be willing to do without this treatment
based on results of their genomic tests.
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Figure 1. Perceived Recurrence Risk
Bars depict standard errors
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Figure 2a. Chemotherapy Treatment Preference.
Figure 2b. Hormone Therapy Treatment Preference.
DeFrank et al. Page 10













Figure 3. Perceived risk as mediator
Values are z statistics from generalized estimable models.
*p<.001
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Table 1




Married or living as married 74
College degree or more 55
Annual household income, > $60,000 60
Insured 95
High literacy (never/rarely needs help) 81
High numeracy (all 3 answers correct) 31
Time since diagnosis, mean (months) 17
Treatment received
 Hormone therapy 92
 Radiation 61
 Chemotherapy 33
Oncotype DX risk category*
 Low (<12%) 51
 Intermediate (12–21%) 37
 High (>21%) 12
Conflicting test results
 Unsure/do not remember 54
 Results were the same 29
 Results were discordant 17
Notes. n=77, except variables with missing data: age (n=75), insurance status (n=76), Oncotype risk category (n=67) due to women who did not
give permission to review their medical records, and conflicting test results (n=76).
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